Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Br J Cancer
    December 2024
  1. XU Q, Kowalski J
    Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer.
    Br J Cancer. 2024;131:1825-1832.
    >> Share

    November 2024
  2. MORGAN RD, Wang X, Barnes BM, Spurgeon L, et al
    Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
    Br J Cancer. 2024 Nov 16. doi: 10.1038/s41416-024-02874.
    >> Share

  3. TAN R, Wen M, Yang W, Zhan D, et al
    Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets.
    Br J Cancer. 2024 Nov 15. doi: 10.1038/s41416-024-02894.
    >> Share

  4. ZAHID MU, Waguespack M, Harman RC, Kercher EM, et al
    Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study.
    Br J Cancer. 2024;131:1378-1386.
    >> Share

    October 2024
  5. HIRAHARA Y, Shimizu K, Yamasaki S, Iyoda T, et al
    Crucial immunological roles of the invasion front in innate and adaptive immunity in cervical cancer.
    Br J Cancer. 2024 Oct 29. doi: 10.1038/s41416-024-02877.
    >> Share

  6. SUN Y, Yin Z, Li S, Wu L, et al
    Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
    Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02863.
    >> Share

    September 2024
  7. YANG X, Wu Y, Ficorella L, Wilcox N, et al
    Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.
    Br J Cancer. 2024 Sep 18. doi: 10.1038/s41416-024-02851.
    >> Share

  8. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    >> Share

  9. SMITH HL, Willmore E, Prendergast L, Curtin NJ, et al
    ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Br J Cancer. 2024;131:905-917.
    >> Share

  10. SUVAAL I, Hummel SB, Mens JM, Tuijnman-Raasveld CC, et al
    Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy: results of a randomised trial.
    Br J Cancer. 2024;131:808-819.
    >> Share

    August 2024
  11. TAKAMATSU S, Hillman RT, Yoshihara K, Baba T, et al
    Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02837.
    >> Share

  12. ZHUO L, Meng F, Sun K, Zhou M, et al
    Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis.
    Br J Cancer. 2024 Aug 2. doi: 10.1038/s41416-024-02803.
    >> Share

    July 2024
  13. NAGLE CM, Ibiebele TI, Bandera EV, Cramer D, et al
    Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2024 Jul 18. doi: 10.1038/s41416-024-02792.
    >> Share

    June 2024
  14. ARONSON SL, Walker C, Thijssen B, van de Vijver KK, et al
    Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02731.
    >> Share

  15. QIU L, Li R, Wang Y, Lu Z, et al
    PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex.
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02749.
    >> Share

    May 2024
  16. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
    >> Share

  17. KENKHUIS MF, Stelten S, Hartman YA, Brouwer CG, et al
    Effects of a combined exercise and dietary intervention on body composition, physical functioning and fatigue in patients with ovarian cancer: results of the PADOVA trial.
    Br J Cancer. 2024 May 8. doi: 10.1038/s41416-024-02694.
    >> Share

  18. HERMAN L, Amo A, Legois B, Di Carlo C, et al
    A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp.
    Br J Cancer. 2024;130:1453-1462.
    >> Share

  19. REBOLJ M, Brentnall AR, Cuschieri K
    Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening.
    Br J Cancer. 2024;130:1733-1743.
    >> Share

  20. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    >> Share

    April 2024
  21. DHAR C, Ramachandran P, Xu G, Pickering C, et al
    Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
    >> Share

  22. PORTNOY A, Pedersen K, Kim JJ, Burger EA, et al
    Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.
    Br J Cancer. 2024 Apr 20. doi: 10.1038/s41416-024-02682.
    >> Share

  23. KMENT J, Newsted D, Young S, Vermeulen MC, et al
    Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
    Br J Cancer. 2024 Apr 15. doi: 10.1038/s41416-024-02677.
    >> Share

  24. TIAN Y, Lin Y, Qu C, Arndt V, et al
    Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
    Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
    >> Share

    March 2024
  25. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Correction: Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02628.
    >> Share

  26. MATOBA Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, et al
    Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
    Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02621.
    >> Share

    February 2024
  27. BAXTER MA, Denholm M, Kingdon SJ, Kathirgamakarthigeyan S, et al
    CAnceR IN PreGnancy (CARING) - a retrospective study of cancer diagnosed during pregnancy in the United Kingdom.
    Br J Cancer. 2024 Feb 21. doi: 10.1038/s41416-024-02605.
    >> Share

  28. ZHENG G, Faber MT, Wang J, Baandrup L, et al
    Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02609.
    >> Share

  29. MONJE N, Dragomir MP, Sinn BV, Hoffmann I, et al
    AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
    Br J Cancer. 2024 Feb 9. doi: 10.1038/s41416-023-02550.
    >> Share

    January 2024
  30. WANG Y, He M, He T, Ouyang X, et al
    Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers.
    Br J Cancer. 2024 Jan 22. doi: 10.1038/s41416-023-02555.
    >> Share

  31. NICUM S, McGregor N, Austin R, Collins L, et al
    Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
    Br J Cancer. 2024 Jan 20. doi: 10.1038/s41416-023-02567.
    >> Share

  32. LANDOLFO C, Ceusters J, Valentin L, Froyman W, et al
    Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery.
    Br J Cancer. 2024 Jan 19. doi: 10.1038/s41416-024-02578.
    >> Share

  33. YOUNG HAN C, Bedia JS, Yang WL, Hawley SJ, et al
    Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
    Br J Cancer. 2024 Jan 9. doi: 10.1038/s41416-023-02560.
    >> Share

  34. LV M, Xu Y, Chen P, Li J, et al
    TSLP enhances progestin response in endometrial cancer via androgen receptor signal pathway.
    Br J Cancer. 2024 Jan 3. doi: 10.1038/s41416-023-02545.
    >> Share

    December 2023
  35. HERRINGTON CS, Oswald AJ, Stillie LJ, Croy I, et al
    Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02508.
    >> Share

  36. ZEBIC DS, Tjokrowidjaja A, Francis KE, Friedlander M, et al
    Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02528.
    >> Share

  37. POSTEL-VINAY S, Coves J, Texier M, Aldea M, et al
    Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02514.
    >> Share

  38. ARTER ZL, Desmond D, Berenberg JL, Killeen JL, et al
    Epithelial ovarian cancer survival by race and ethnicity in an equal-access healthcare population.
    Br J Cancer. 2023 Dec 6. doi: 10.1038/s41416-023-02471.
    >> Share

    November 2023
  39. DOWNHAM L, Jaafar I, Rol ML, Nyawira Nyaga V, et al
    Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis.
    Br J Cancer. 2023 Nov 16. doi: 10.1038/s41416-023-02490.
    >> Share

  40. VALCARCEL-JIMENEZ L, Frezza C
    Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism.
    Br J Cancer. 2023;129:1546-1557.
    >> Share

  41. ALLAN Z, Witts S, Tie J, Tebbutt N, et al
    The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review.
    Br J Cancer. 2023;129:1717-1726.
    >> Share

    October 2023
  42. JIN Q, Gheeya J, Nepal S, Shi N, et al
    Associations of dietary patterns with kidney cancer risk, kidney cancer-specific mortality and all-cause mortality among postmenopausal women.
    Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02469.
    >> Share

  43. PETRICK JL, Joslin CE, Johnson CE, Camacho TF, et al
    Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
    Br J Cancer. 2023 Oct 21. doi: 10.1038/s41416-023-02407.
    >> Share

  44. PARK J, Kim JC, Lee M, Lee J, et al
    Frequency of peripheral PD-1(+)regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.
    Br J Cancer. 2023 Oct 11. doi: 10.1038/s41416-023-02455.
    >> Share

  45. PLEUNIS N, Pouwer AW, Oonk MHM, van Doorn HC, et al
    Incidence of inguinofemoral lymph node metastases at the first local recurrence of vulvar cancer: a Dutch nationwide study.
    Br J Cancer. 2023;129:956-964.
    >> Share

  46. BHAMIDIPATI D, Haro-Silerio JI, Yap TA, Ngoi N, et al
    PARP inhibitors: enhancing efficacy through rational combinations.
    Br J Cancer. 2023;129:904-916.
    >> Share

    August 2023
  47. CHOI JA, Kim H, Kwon H, Lee EH, et al
    Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.
    Br J Cancer. 2023 Aug 18. doi: 10.1038/s41416-023-02355.
    >> Share

  48. CUSCHIERI K, Palmer T, Graham C, Cameron R, et al
    The changing nature of HPV associated with high grade cervical lesions in vaccinated populations, a retrospective study of over 1700 cases in Scotland.
    Br J Cancer. 2023 Aug 10. doi: 10.1038/s41416-023-02386.
    >> Share

  49. JOHNSON CE, Alberg AJ, Bandera EV, Peres LC, et al
    Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women.
    Br J Cancer. 2023 Aug 3. doi: 10.1038/s41416-023-02385.
    >> Share

  50. THAVANESWARAN S, Kansara M, Lin F, Espinoza D, et al
    A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
    Br J Cancer. 2023;129:475-485.
    >> Share

    July 2023
  51. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    >> Share

  52. ZHANG Z, Zhang M, Zhou J, Wang D, et al
    Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy.
    Br J Cancer. 2023 Jul 4. doi: 10.1038/s41416-023-02347.
    >> Share

  53. KERRISON RS, Jones A, Peng J, Price G, et al
    Inequalities in cancer screening participation between adults with and without severe mental illness: results from a cross-sectional analysis of primary care data on English Screening Programmes.
    Br J Cancer. 2023;129:81-93.
    >> Share

    June 2023
  54. KAO WH, Kuo CF, Chang CC, Liu YC, et al
    Cancer survivorship and risk of pregnancy complications, adverse obstetric outcomes, and maternal morbidities in female adolescents and young adults: a nationwide population-based study from Taiwan.
    Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02333.
    >> Share

  55. YANG Z, Wang XL, Bai R, Liu WY, et al
    Retraction Note: miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
    Br J Cancer. 2023 Jun 26. doi: 10.1038/s41416-023-02328.
    >> Share

    May 2023
  56. PEREMIQUEL-TRILLAS P, Gomez D, Martinez JM, Fernandez-Gonzalez S, et al
    Cost-effectiveness analysis of molecular testing in minimally invasive samples to detect endometrial cancer in women with postmenopausal bleeding.
    Br J Cancer. 2023 May 10. doi: 10.1038/s41416-023-02291.
    >> Share

    April 2023
  57. QUINTELA M, James DW, Garcia J, Edwards K, et al
    In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
    Br J Cancer. 2023 Apr 29. doi: 10.1038/s41416-023-02274.
    >> Share

  58. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
    Evaluation of DNA methylation biomarkers ASCL1 and LHX8 on HPV-positive self-collected samples from primary HPV-based screening.
    Br J Cancer. 2023 Apr 26:1-8. doi: 10.1038/s41416-023-02277.
    >> Share

  59. O'MAHONY DG, Ramus SJ, Southey MC, Meagher NS, et al
    Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02263.
    >> Share

  60. KAMAL M, Lameiras S, Deloger M, Morel A, et al
    Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
    Br J Cancer. 2023 Apr 13. doi: 10.1038/s41416-023-02261.
    >> Share

  61. MARTIN AL, Colin-Leitzinger CM, Sinha SK, Chern JY, et al
    Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.
    Br J Cancer. 2023 Apr 6. doi: 10.1038/s41416-023-02259.
    >> Share

    March 2023
  62. LONG X, Lu H, Cai MC, Zang J, et al
    APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
    Br J Cancer. 2023 Mar 30. doi: 10.1038/s41416-023-02239.
    >> Share

  63. MITTELSTADT S, Kelemen O, Admard J, Gschwind A, et al
    Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse.
    Br J Cancer. 2023 Mar 27. doi: 10.1038/s41416-023-02233.
    >> Share

  64. GILHAM C, Sargent A, Crosbie EJ, Peto J, et al
    Long-term risks of invasive cervical cancer following HPV infection: follow-up of two screening cohorts in Manchester.
    Br J Cancer. 2023 Mar 23. doi: 10.1038/s41416-023-02227.
    >> Share

    February 2023
  65. WALKER TDJ, Faraahi ZF, Price MJ, Hawarden A, et al
    The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
    Br J Cancer. 2023 Feb 21. doi: 10.1038/s41416-023-02168.
    >> Share

  66. NJOKU K, Pierce A, Geary B, Campbell AE, et al
    Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.
    Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02139.
    >> Share

  67. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2023 Feb 16. doi: 10.1038/s41416-023-02205.
    >> Share

  68. ASAMI Y, Kobayashi Kato M, Hiranuma K, Matsuda M, et al
    Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer.
    Br J Cancer. 2023 Feb 16. doi: 10.1038/s41416-023-02203.
    >> Share

  69. COLOMBO N, Gadducci A, Sehouli J, Rulli E, et al
    INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 m
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-022-02108.
    >> Share

  70. LEYDEN GM, Greenwood MP, Gaborieau V, Han Y, et al
    Disentangling the aetiological pathways between body mass index and site-specific cancer risk using tissue-partitioned Mendelian randomisation.
    Br J Cancer. 2023;128:618-625.
    >> Share

    January 2023
  71. KRALJ J, Pernar Kovac M, Dabelic S, Polancec DS, et al
    Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02140.
    >> Share

  72. VERMIJ L, Jobsen JJ, Leon-Castillo A, Brinkhuis M, et al
    Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
    Br J Cancer. 2023 Jan 23. doi: 10.1038/s41416-023-02141.
    >> Share

  73. TAKAMATSU S, Yoshihara K, Baba T, Shimada M, et al
    Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122.
    >> Share

    December 2022
  74. SANDVEI MS, Pinborg A, Gissler M, Bergh C, et al
    Risk of ovarian cancer in women who give birth after assisted reproductive technology (ART)-a registry-based Nordic cohort study with follow-up from first pregnancy.
    Br J Cancer. 2022 Dec 22. doi: 10.1038/s41416-022-02097.
    >> Share

  75. IBRAHIM SL, Abed MN, Mohamed G, Price JC, et al
    Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.
    Br J Cancer. 2022 Dec 16. doi: 10.1038/s41416-022-02095.
    >> Share

  76. COSTA S, Verberckmoes B, Castle PE, Arbyn M, et al
    Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening.
    Br J Cancer. 2022 Dec 14. doi: 10.1038/s41416-022-02094.
    >> Share

  77. KRISTELEIT RS, Drew Y, Oza AM, Domchek SM, et al
    Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02022.
    >> Share

  78. BERG HF, Engerud H, Myrvold M, Lien HE, et al
    Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02063.
    >> Share

  79. MURUMAGI A, Ungureanu D, Khan S, Arjama M, et al
    Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
    Br J Cancer. 2022 Dec 7. doi: 10.1038/s41416-022-02067.
    >> Share

    November 2022
  80. BAX HJ, Chauhan J, Stavraka C, Santaolalla A, et al
    Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
    Br J Cancer. 2022 Nov 19. doi: 10.1038/s41416-022-02031.
    >> Share

  81. WEIR A, Kang EY, Meagher NS, Nelson GS, et al
    Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
    Br J Cancer. 2022 Nov 2. pii: 10.1038/s41416-022-02014.
    >> Share

    September 2022
  82. OCHS-BALCOM HM, Johnson C, Guertin KA, Qin B, et al
    Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01981.
    >> Share

  83. CHEN Y, Wang DD, Wu YP, Su D, et al
    Correction To: MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2022 Sep 15. pii: 10.1038/s41416-022-01984.
    >> Share

  84. ABIKO K, Hamanishi J, Matsumura N, Mandai M, et al
    Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
    Br J Cancer. 2022 Sep 6. pii: 10.1038/s41416-022-01960.
    >> Share

    August 2022
  85. AASBO G, Trope A, Nygard M, Christiansen IK, et al
    HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01954.
    >> Share

  86. GAHLAWAT AW, Witte T, Haarhuis L, Schott S, et al
    A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
    Br J Cancer. 2022 Aug 5. pii: 10.1038/s41416-022-01925.
    >> Share

    July 2022
  87. MUSACCHIO L, Califano D, Bartoletti M, Arenare L, et al
    Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    Br J Cancer. 2022 Jul 22. pii: 10.1038/s41416-022-01897.
    >> Share

  88. NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
    Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
    Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
    >> Share

    June 2022
  89. SASAMOTO N, Wang T, Townsend MK, Eliassen AH, et al
    Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer.
    Br J Cancer. 2022 Jun 27. pii: 10.1038/s41416-022-01901.
    >> Share

  90. BEINSE G, Just PA, Le Frere Belda MA, Laurent-Puig P, et al
    Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    Br J Cancer. 2022 Jun 25. pii: 10.1038/s41416-022-01900.
    >> Share

  91. KAMAT K, Krishnan V, Dorigo O
    Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.
    Br J Cancer. 2022 Jun 24. pii: 10.1038/s41416-022-01887.
    >> Share

  92. HERBST J, Pantel K, Effenberger K, Wikman H, et al
    Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01868.
    >> Share

  93. BRANTLEY KD, Zeleznik OA, Dickerman BA, Balasubramanian R, et al
    A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
    Br J Cancer. 2022 Jun 18. pii: 10.1038/s41416-022-01873.
    >> Share

  94. HOLLIS RL, Croy I, Churchman M, Bartos C, et al
    Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01874.
    >> Share

  95. KOTSOPOULOS J, Zamani N, Rosen B, McLaughlin JR, et al
    Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    Br J Cancer. 2022 Jun 16. pii: 10.1038/s41416-022-01840.
    >> Share

  96. DI MARTINO E, Smith L, Bradley SH, Hemphill S, et al
    Incidence trends for twelve cancers in younger adults-a rapid review.
    Br J Cancer. 2022;126:1374-1386.
    >> Share

    May 2022
  97. MENON U, Weller D, Falborg AZ, Jensen H, et al
    Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01844.
    >> Share

  98. CHEN T, Yu T, Zhuang S, Geng Y, et al
    Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01836.
    >> Share

  99. EL HELALI A, Plummer R, Jayson GC, Coyle VM, et al
    A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
    Br J Cancer. 2022 May 14. pii: 10.1038/s41416-022-01780.
    >> Share

    April 2022
  100. CREMONA M, Vandenberg CJ, Farrelly AM, Madden SF, et al
    BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    Br J Cancer. 2022 Apr 30. pii: 10.1038/s41416-022-01823.
    >> Share

  101. JI M, Jiang S, Zhao J, Wan X, et al
    Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia.
    Br J Cancer. 2022 Apr 22. pii: 10.1038/s41416-022-01809.
    >> Share

  102. KOIZUME S, Takahashi T, Nakamura Y, Yoshihara M, et al
    Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01808.
    >> Share

  103. SHAKFA N, Li D, Nersesian S, Wilson-Sanchez J, et al
    The STING pathway: Therapeutic vulnerabilities in ovarian cancer.
    Br J Cancer. 2022 Apr 5. pii: 10.1038/s41416-022-01797.
    >> Share

  104. KONSTANTINOPOULOS PA, Cheng SC, Supko JG, Polak M, et al
    Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    Br J Cancer. 2022;126:1027-1036.
    >> Share

    March 2022
  105. YOU B, Van Wagensveld L, Tod M, Sonke GS, et al
    Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    Br J Cancer. 2022 Mar 31. pii: 10.1038/s41416-022-01732.
    >> Share

  106. REBOLJ M, Pesola F, Mathews C, Mesher D, et al
    The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01791.
    >> Share

  107. SEITZ S, Dreyer TF, Stange C, Steiger K, et al
    CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
    Br J Cancer. 2022 Mar 21. pii: 10.1038/s41416-022-01763.
    >> Share

  108. MORGAN RD, Burghel GJ, Flaum N, Bulman M, et al
    BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    Br J Cancer. 2022 Mar 8. pii: 10.1038/s41416-022-01773.
    >> Share

    February 2022
  109. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01717.
    >> Share

    January 2022
  110. YE S, Li Q, Wu Y, Jiang W, et al
    Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma.
    Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01705.
    >> Share

  111. MUKAMA T, Fortner RT, Katzke V, Hynes LC, et al
    Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
    Br J Cancer. 2022 Jan 14. pii: 10.1038/s41416-021-01697.
    >> Share

  112. SUN J, Yan C, Xu D, Zhang Z, et al
    Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
    Br J Cancer. 2022 Jan 11. pii: 10.1038/s41416-021-01692.
    >> Share

    December 2021
  113. FOTOPOULOU C, Rockall A, Lu H, Lee P, et al
    Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
    Br J Cancer. 2021 Dec 18. pii: 10.1038/s41416-021-01662.
    >> Share

    November 2021
  114. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    >> Share

  115. DICK S, Vink FJ, Heideman DAM, Lissenberg-Witte BI, et al
    Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.
    Br J Cancer. 2021 Nov 6. pii: 10.1038/s41416-021-01614.
    >> Share

  116. GUFFANTI F, Alvisi MF, Anastasia A, Ricci F, et al
    Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Br J Cancer. 2021 Nov 3. pii: 10.1038/s41416-021-01609.
    >> Share

    October 2021
  117. MURPHY AD, Morgan RD, Clamp AR, Jayson GC, et al
    The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    Br J Cancer. 2021 Oct 29. pii: 10.1038/s41416-021-01605.
    >> Share

  118. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    >> Share

  119. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    >> Share

  120. XIE SH, Santoni G, Lagergren J
    Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01575.
    >> Share

    September 2021
  121. CRISPIN-ORTUZAR M, Sala E
    Precision radiogenomics: fusion biopsies to target tumour habitats in vivo.
    Br J Cancer. 2021;125:778-779.
    >> Share

    March 2021
  122. EINBOND LS, Zhou J, Wu HA, Mbazor E, et al
    A novel cancer preventative botanical mixture, TriCurin, inhibits viral transcripts and the growth of W12 cervical cells harbouring extrachromosomal or integrated HPV16 DNA.
    Br J Cancer. 2021;124:901-913.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016